Definium Therapeutics reported net income of -$159.39M for the quarter ended Jun 2026. This income statement covers 23 quarters of results from Dec 2020 through Jun 2026, standardized by Business Quant from the company’s SEC filings.
| Income Statement | Dec2020 | Mar2021 | Jun2021 | Sep2021 | Dec2021 | Mar2022 | Jun2022 | Sep2022 | Dec2022 | Mar2023 | Jun2023 | Sep2023 | Dec2023 | Mar2024 | Jun2024 | Sep2024 | Dec2024 | Mar2025 | Jun2025 | Sep2025 | Dec2025 | Mar2026 | Jun2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Shares Outstanding (Entity)Shares Outstanding (Entity.) | 28.08M | 28.13M | 28.16M | 28.45M | 29.30M | 30.86M | 38.29M | 38.81M | 40.09M | 41.10M | 47.86M | 72.08M | 81.59M | 75.10M | 75.51M | 75.80M | 76.77M | 98.78M | 104.04M | 110.68M | |||
| Operating items | |||||||||||||||||||||||
| Research & DevelopmentR&D | 9.02M | 10.88M | 10.24M | 9.33M | 7.77M | 8.83M | 12.60M | 14.78M | 13.20M | 11.55M | 11.71M | 14.64M | 17.19M | 21.76M | 23.36M | 29.81M | 30.98M | 33.56M | 41.48M | 48.66M | |||
| Selling, General & AdministrativeSG&A | 8.21M | 6.67M | 8.26M | 7.62M | 9.21M | 5.07M | 8.26M | 14.41M | 8.41M | 10.66M | 10.50M | 9.81M | 7.60M | 10.70M | 8.80M | 11.09M | 14.69M | 14.06M | 17.74M | 26.41M | |||
| Other Operating ExpensesOther Opex | -0.00M | -0.04M | |||||||||||||||||||||
| Operating ExpensesOpex | 17.23M | 17.56M | 18.50M | 16.94M | 16.98M | 13.90M | 20.86M | 29.18M | 21.62M | 22.20M | 22.20M | 24.46M | 24.79M | 32.46M | 32.16M | 40.90M | 45.67M | 47.58M | 59.22M | 75.08M | |||
| Operating IncomeOp. Inc | -17.23M | -17.56M | -18.50M | -16.94M | -16.98M | -13.90M | -20.86M | -29.18M | -21.62M | -22.20M | -22.20M | -24.46M | -24.79M | -32.46M | -32.16M | -40.90M | -45.67M | -47.58M | -59.22M | -75.08M | |||
| EBIT | -17.23M | -17.56M | -18.50M | -16.94M | -16.98M | -13.90M | -20.86M | -29.18M | -21.62M | -22.20M | -22.20M | -24.46M | -24.79M | -32.46M | -32.16M | -40.90M | -45.67M | -47.58M | -59.22M | -75.08M | |||
| Non-operating items | |||||||||||||||||||||||
| Non Operating Interest Expenses | 0.08M | 0.08M | 0.33M | 0.44M | 0.43M | 0.47M | 0.73M | 0.66M | 0.60M | 2.34M | 1.30M | 1.29M | 1.25M | 1.23M | |||||||||
| Non Operating Investment Income | 0.01M | 0.04M | 0.20M | 0.09M | -0.26M | -0.41M | |||||||||||||||||
| Interest & Investment IncomeInt & Inv Inc | 1.36M | 1.39M | 1.49M | 1.34M | 1.66M | 3.12M | 3.51M | 3.28M | 2.43M | 2.77M | 2.26M | 3.49M | 3.46M | 3.59M | |||||||||
| Other Non Operating IncomeOther Non Op Inc. | -0.04M | -12.71M | 0.05M | -0.09M | 0.50M | 9.00M | -3.95M | 0.25M | 3.69M | -1.62M | -32.20M | 18.60M | 11.11M | -7.30M | 8.81M | -1.84M | -21.60M | -2.86M | -17.88M | -83.91M | |||
| Net income details | |||||||||||||||||||||||
| EBT | -17.20M | -17.99M | -18.50M | -16.96M | -16.48M | -9.87M | -19.58M | -27.87M | -20.45M | -21.30M | -20.98M | -21.81M | -22.01M | -29.84M | -30.33M | -40.47M | -44.71M | -45.37M | -57.01M | -72.72M | |||
| Tax ProvisionsTaxes | -19.78M | -11.93M | |||||||||||||||||||||
| Profit After TaxPAT | -17.58M | -16.83M | -18.50M | -17.10M | -16.59M | -5.02M | -24.82M | -29.41M | -17.92M | -24.15M | -53.91M | -5.86M | -22.04M | -34.74M | -23.36M | -42.74M | -67.27M | -50.44M | -77.36M | -159.39M | |||
| Income from Continuing OperationsIncome (Continuing) | -17.20M | 1.79M | -18.50M | -16.96M | -16.48M | 2.06M | -19.58M | -27.87M | -20.45M | -21.30M | -20.98M | -21.81M | -22.01M | -29.84M | -30.33M | -40.47M | -44.71M | -45.37M | -57.01M | -72.72M | |||
| Consolidated Net IncomeConsol Net Inc. | -17.20M | 1.79M | -18.50M | -16.96M | -16.48M | 2.06M | -19.58M | -27.87M | -20.45M | -21.30M | -20.98M | -21.81M | -22.01M | -29.84M | -30.33M | -40.47M | -44.71M | -45.37M | -57.01M | -72.72M | |||
| Income towards Parent CompanyParent Net Inc | -17.20M | 1.79M | -18.50M | -16.96M | -16.48M | 2.06M | -19.58M | -27.87M | -20.45M | -21.30M | -20.98M | -21.81M | -22.01M | -29.84M | -30.33M | -40.47M | -44.71M | -45.37M | -57.01M | -72.72M | |||
| Net Income towards Common StockholdersNet Income | -17.20M | 1.79M | -18.50M | -16.96M | -16.48M | 2.06M | -19.58M | -27.87M | -20.45M | -21.30M | -54.40M | -5.85M | -13.68M | -34.74M | -23.35M | -42.74M | -67.27M | -50.44M | -77.10M | -158.99M | |||
| Additional items | |||||||||||||||||||||||
| EPS (Basic) | -0.61 | 0.07 | -0.66 | -0.60 | -0.56 | 0.07 | -0.51 | -0.72 | -0.51 | -0.54 | -1.14 | -0.08 | -0.18 | -0.49 | -0.27 | -0.50 | -0.78 | -0.56 | -0.71 | -1.44 | |||
| EPS (Diluted) | -0.61 | 0.07 | -0.66 | -0.60 | -0.56 | 0.07 | -0.51 | -0.72 | -0.51 | -0.54 | -1.14 | -0.08 | -0.17 | -0.49 | -0.27 | -0.50 | -0.78 | -0.56 | -0.71 | -1.44 | |||
| Shares Outstanding | 28.01M | 27.38M | 28.15M | 28.24M | 29.30M | 30.86M | 38.08M | 38.58M | 39.72M | 39.16M | 47.86M | 71.91M | 77.91M | 70.46M | 85.07M | 85.35M | 85.89M | 89.33M | 108.79M | 110.68M | |||
| Shares Outstanding (Diluted)Shares Outstanding (Dil.) | 28.01M | 27.38M | 28.15M | 28.24M | 29.30M | 30.86M | 38.08M | 38.58M | 39.72M | 39.16M | 47.86M | 75.30M | 80.24M | 70.46M | 87.09M | 85.35M | 85.89M | 89.33M | 108.79M | 110.68M | |||
| EBITDA | -17.23M | -17.56M | -18.50M | -16.94M | -16.98M | -13.90M | -20.86M | -29.18M | -21.62M | -22.20M | -22.20M | -24.46M | -24.79M | -32.46M | -32.16M | -40.90M | -45.67M | -47.58M | -59.22M | -75.08M | |||
| Interest ExpensesInt Expense | 0.08M | 0.08M | 0.33M | 0.44M | 0.43M | 0.47M | 0.73M | 0.66M | 0.60M | 2.34M | 1.30M | 1.29M | 1.25M | 1.23M | |||||||||
| Tax Rate | 109.98 | 120.83 |